rawfin.tv
Exelixis Highlights Zanzalintinib at Wells Fargo Healthcare Conference
MarketsstocksAI Generated

Exelixis Highlights Zanzalintinib at Wells Fargo Healthcare Conference

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Exelixis discussed its business transition and pipeline at the Wells Fargo 21st Annual Healthcare Conference. The company emphasized its drug zanzalintinib, alongside CABOMETYX, as key to its future strategy.

BiotechnologyPharmaceuticalsHealthcare ConferenceDrug Pipeline

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks